Effects of MK-7 Supplementation on Glycemic Status, Anthropometric Indices and Lipid Profile in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
MK-7
anthropometric indices
diabetes
dyslipidemia
glycemic status
menaquinone
phylloquinone
vitamin K
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
03
2020
accepted:
11
06
2020
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
4
7
2020
Statut:
epublish
Résumé
Type 2 diabetes mellitus (T2DM) is a prevalent disorder which accounts for 90-95% of diabetic patients. The aim of this study was to assess the effects of menaquinone (MK-7) supplementation on glycemic indices, anthropometric indices and lipid profile, among patients with T2DM. In this double-blind placebo-controlled randomized clinical trial, 60 men and women with T2DM were allocated equally into either the MK-7 (200 µg/day) or the placebo group. Physical activity level and dietary intake were assessed using the international physical activity questionnaire-short form (IPAQ-SF) and a 3-day food record, pre- and post-intervention. Anthropometric measures, blood pressure, glycemic indices and lipid profile including fasting blood sugar (FBS), hemoglobin A1c (HBA1C), fasting insulin (FI), homeostatic model assessment insulin resistance index (HOMA-IR), triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C) were measured at baseline and after twelve weeks. Forty-five patients completed the trial. There were no significant between-group differences for calorie intake, macronutrient intake, physical activity level or anthropometric measures at baseline and at the end of the study. Dietary vitamin K intake increased significantly at the end of the study in the MK-7 ( MK-7 supplementation seems to be effective in the improvement of glycemic indices, but not the lipid profile of patients with T2DM. The present study was prospectively registered at the Iranian Registry of Clinical Trials on May 2019 (ID: IRCT20100123003140N22).
Sections du résumé
BACKGROUND
BACKGROUND
Type 2 diabetes mellitus (T2DM) is a prevalent disorder which accounts for 90-95% of diabetic patients. The aim of this study was to assess the effects of menaquinone (MK-7) supplementation on glycemic indices, anthropometric indices and lipid profile, among patients with T2DM.
METHODS
METHODS
In this double-blind placebo-controlled randomized clinical trial, 60 men and women with T2DM were allocated equally into either the MK-7 (200 µg/day) or the placebo group. Physical activity level and dietary intake were assessed using the international physical activity questionnaire-short form (IPAQ-SF) and a 3-day food record, pre- and post-intervention. Anthropometric measures, blood pressure, glycemic indices and lipid profile including fasting blood sugar (FBS), hemoglobin A1c (HBA1C), fasting insulin (FI), homeostatic model assessment insulin resistance index (HOMA-IR), triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C) were measured at baseline and after twelve weeks.
RESULTS
RESULTS
Forty-five patients completed the trial. There were no significant between-group differences for calorie intake, macronutrient intake, physical activity level or anthropometric measures at baseline and at the end of the study. Dietary vitamin K intake increased significantly at the end of the study in the MK-7 (
CONCLUSION
CONCLUSIONS
MK-7 supplementation seems to be effective in the improvement of glycemic indices, but not the lipid profile of patients with T2DM.
CLINICAL TRIAL REGISTRATION
BACKGROUND
The present study was prospectively registered at the Iranian Registry of Clinical Trials on May 2019 (ID: IRCT20100123003140N22).
Identifiants
pubmed: 32617013
doi: 10.2147/DMSO.S253014
pii: 253014
pmc: PMC7326202
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2239-2249Informations de copyright
© 2020 Karamzad et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Drug Res (Stuttg). 2018 Jul;68(7):403-409
pubmed: 29458218
Biochem Biophys Res Commun. 2003 Dec 26;312(4):1118-22
pubmed: 14651988
Nutrients. 2016 Jan 02;8(1):
pubmed: 26729160
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Nutrition. 2015 Oct;31(10):1284-92
pubmed: 26333893
Am J Clin Nutr. 2000 Aug;72(2):490-5
pubmed: 10919946
Br J Nutr. 2012 Sep 28;108(6):1017-24
pubmed: 22136751
Nutrition. 2018 Mar;47:33-38
pubmed: 29429532
Am J Clin Nutr. 2012 Nov;96(5):1113-8
pubmed: 23034962
J Am Coll Nutr. 2009 Aug;28(4):369-79
pubmed: 20368375
Diabetes Res Clin Pract. 2014 Feb;103(2):137-49
pubmed: 24630390
J Nutr Biochem. 2010 Nov;21(11):1120-6
pubmed: 20149620
Exp Clin Endocrinol Diabetes. 2014 Jul;122(7):384-6
pubmed: 25014088
Am J Clin Nutr. 2008 Jul;88(1):210-5
pubmed: 18614743
Am J Clin Nutr. 2008 Aug;88(2):356-63
pubmed: 18689371
Clin Chim Acta. 2007 May 1;380(1-2):24-30
pubmed: 17343838
Diabetes Care. 2008 Nov;31(11):2092-6
pubmed: 18697901
Nutrition. 2015 Jan;31(1):214-22
pubmed: 25466668
Exp Eye Res. 2014 Nov;128:73-82
pubmed: 25257692
Diabetes Res Clin Pract. 2018 Feb;136:39-51
pubmed: 29196151
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
J Diabetes Metab Disord. 2015 Jan 14;14(1):1
pubmed: 25654061
J Nutr Biochem. 2018 Feb;52:103-114
pubmed: 29175667
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Thromb Haemost. 2008 Oct;100(4):530-47
pubmed: 18841274
Diabetes Care. 2010 Aug;33(8):1699-705
pubmed: 20424220
Diabetes Care. 2000 Aug;23(8):1103-7
pubmed: 10937505
Calcif Tissue Int. 2011 Feb;88(2):162-8
pubmed: 21136047
J Diabetes Investig. 2019 Nov;10(6):1405-1407
pubmed: 31472101
Am J Clin Nutr. 2019 Oct 1;110(4):883-890
pubmed: 31387121
J Clin Endocrinol Metab. 2015 Jun;100(6):2472-9
pubmed: 25835288
Food Nutr Res. 2012;56:
pubmed: 22489217
Mol Metab. 2013 Apr 19;2(3):133-41
pubmed: 24049728
Horm Metab Res. 2018 Mar;50(3):227-235
pubmed: 29523009
Biochimie. 2012 Oct;94(10):2137-42
pubmed: 22713764
J Bone Miner Metab. 2014 Mar;32(2):142-50
pubmed: 23702931
BMJ Open. 2017 May 9;7(5):e015910
pubmed: 28487462
Food Funct. 2018 Jan 24;9(1):450-462
pubmed: 29227493
Diabetes Metab Res Rev. 2009 Nov;25(8):768-72
pubmed: 19877133
Nutrition. 2016 Jul-Aug;32(7-8):732-9
pubmed: 27133809
Nat Med. 2001 Aug;7(8):941-6
pubmed: 11479627
Bone. 2000 Dec;27(6):769-76
pubmed: 11113387
Br J Nutr. 2016 Jul;116(2):286-93
pubmed: 27198036
Biofactors. 2020 Jan;46(1):21-37
pubmed: 31573736
Eur J Clin Nutr. 2015 Aug;69(8):891-5
pubmed: 25782427
Biochim Biophys Acta. 2002 Feb 15;1570(1):27-32
pubmed: 11960685
Plant J. 2012 Jul;71(2):205-15
pubmed: 22372525
J Biol Chem. 2008 Jul 18;283(29):20015-26
pubmed: 18482975